Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca: Our Next Growth Pick
10:52pm, Tuesday, 03'rd May 2022
After the Alexion maxi-acquisition, the company beat both revenue and EPS consensus. Premium pipelines deserve a premium valuation.
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
04:33pm, Friday, 29'th Apr 2022
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
AstraZeneca CEO: ‘each of our businesses grew a lot in Q1'
01:27pm, Friday, 29'th Apr 2022
AstraZeneca plc (LON: AZN) on Friday said vaccine contracts helped its Q1 financial results. Moving forward, however, it expects COVID-related sales to sink by 21% to 25%.
We expect slight decline in China due to price pressures, AstraZeneca CEO says
08:36am, Friday, 29'th Apr 2022
Pascal Soriot discusses the company's performance in China and the prospect for future M&A.
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
06:12am, Friday, 29'th Apr 2022
AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicin
AstraZeneca Beats Estimates, but Warns Demand for Covid Vaccine Will Fade
04:46am, Friday, 29'th Apr 2022
The Anglo-Swedish drugmaker reported sales of $11.4 billion, above the analyst consensus for $10.9 billion.
AstraZeneca beats profit and revenue forecasts; to open new R&D site
03:20am, Friday, 29'th Apr 2022
AstraZeneca PLC (LSE:AZN) repeated its guidance for the full year after it reported forecast-beating results for the first quarter, boosted by sales of its diabetes drug and Covid-19 vaccine. The phar
AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales decline
02:46am, Friday, 29'th Apr 2022
AstraZeneca PLC said Friday that it expects sales of its Covid-19 medicines, including its vaccine, to decline by a low-to-mid twenties percentage during the year, but reported higher revenue in the f
AstraZeneca beats Q1 estimates, keeps 2022 forecasts
02:40am, Friday, 29'th Apr 2022
(Reuters) -AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decli
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
12:02pm, Thursday, 28'th Apr 2022
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb
12:03pm, Wednesday, 27'th Apr 2022
Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S.
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
07:15am, Monday, 25'th Apr 2022
The FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (durvalumab) for unresectable hepatocellular carcino
AstraZeneca says tremelimumab accepted for US Priority Review for Imfinzi combo for liver cancer treatment
02:39am, Monday, 25'th Apr 2022
AstraZeneca PLC (LSE:AZN) said its Biologics License Application (BLA) for tremelimumab, an anti-CTLA4 antibody, has been accepted for Priority Review in the US for patients with unresectable liver c
These Dividend Stocks Are Trouncing the Market -- Are They Still Buys?
05:52am, Sunday, 24'th Apr 2022
Investors don't like these stocks only because of their dividends.
2 Dividend Stocks to Buy and Hold Forever
11:45am, Friday, 22'nd Apr 2022
These two companies have been around a while.
